Novartis has opened a new front in its push into digital health. The latest move sees the Big Pharma bring its navigation app for visually impaired people to Apple and Google's smartwatch platforms.
Eisai has become the latest in a long line of companies to look to IT outsourcing for cost savings. The drugmaker has handed responsibility for the maintenance, operation and monitoring of much of its IT infrastructure in Japan and the U.S. to Accenture in a pair of long-term deals. Accenture is contracted to do the work in Japan until 2024 and in the U.S. until 2022. Only a portion of Eisai's R&D network is excluded from the 7-year U.S. deal, while the agreement in Japan goes beyond servers and other IT infrastructure to cover some of its accounting, production management and other enterprise resource planning systems. The idea is to increase efficiencies through the establishment of a global governance structure and drive down IT costs, prospects that have been luring drugmakers to strike outsourcing deals for years. Read more >>
POPULAR COMMENT THREADS
A congressman is taking aim at perceived flaws in FDA's long-awaited, much-discussed guidance on the use of Twitter.
Deep Genomics has opened its doors. The University of Toronto spinout is working to explore the potential of applying deep learning to genomics, first as a way to improve genetic testing.
Jun Wang has stepped down as CEO of BGI. Wang, a 16-year veteran of BGI, led the business as it evolved into a dominant force in genomics, but has now decided to pursue his long-standing interest in artificial intelligence without the burden of also serving as CEO.
The board of governors at the Patient-Centered Outcomes Research Institute has signed off on an $142.5 million investment in PCORnet, an attempt to mine ever-growing repositories of health and clinical data for research.
Ginkgo Bioworks has landed $45 million in a Series B round. The money will facilitate a significant scaling up of operations at the synthetic biology pioneer, with an expansion into pharmaceuticals, construction of a second-generation lab and hiring of new staff all on the cards.
Oxford Nanopore has added $109 million to its bank account, bringing the total raised to date up to $392 million and equipping the company for a vital period in its history
From Our Sister Sites
Former Allergan CEO David Pyott and activist investor Bill Ackman called each other plenty of things during last year's months-long Valeant-Allergan takeover battle. But Pyott had a new one during a Senate committee hearing on Thursday.
ResMed increased its focus on sleep disorder devices by acquiring China's Curative Medical for an undisclosed sum, in an attempt to gain a foothold in a fast-growing market.